Cube Biotech Announces CEO Transition: Michael Bencak Appointed as New Chief Executive Officer
July 17nd, 2025 - Monheim am Rhein, Germany
MONHEIM, Germany, July 17, 2025 -- Cube Biotech, a leading innovator in protein stabilization and purification technologies, announced a leadership transition that marks a significant milestone in the company’s continued global growth. Didier Dargent, who has served as Chief Executive Officer, will transition into the role of Executive Chairman. Michael Bencak has been appointed as the new CEO of Cube Biotech and IBA Lifescience, effective immediately.
Reflecting on the transition, Didier Dargent stated: “It’s been an incredible journey leading Cube Biotech, and I’m proud of what we’ve achieved. As I take on the role of Executive Chairman, I’m confident in Michael’s ability to guide the company into its next phase. With his leadership, we are well-positioned to expand globally and deepen our impact across the biotech sector.”
Michael Bencak joins Cube Biotech with a proven track record of leading biotech organizations through growth, transformation, and innovation. With deep industry insight and a passion for advancing science, Bencak is poised to build on Cube Biotech’s legacy of excellence.
“I’m incredibly excited to join Cube Biotech and IBA Lifescience,” said Bencak. “These companies are uniquely positioned to shape the future of drug discovery. What inspired me to join is not only the science, but the passion, purpose, and ambition behind it. I truly believe we have the chance to make a meaningful difference.”
About Cube Biotech – Pioneering Protein Technologies to Enable Drug Discovery At Cube Biotech, we specialize in the purification, stabilization, and functional screening of proteins — tackling some of the most complex membrane protein targets in biomedical research. As enablers of drug discovery, we support scientists in unlocking the full therapeutic potential of proteins. Following our merger with IBA Life Sciences and with the strategic support of ARCHIMED, we are accelerating innovation, expanding our global reach, and streamlining services across the entire protein research value chain. Our latest advancement: a proprietary automation technology that enables scalable membrane protein production, providing researchers with the tools to drive structural biology, screening campaigns, and therapeutic development with exceptional efficiency and reproducibility.
Reflecting on the transition, Didier Dargent stated: “It’s been an incredible journey leading Cube Biotech, and I’m proud of what we’ve achieved. As I take on the role of Executive Chairman, I’m confident in Michael’s ability to guide the company into its next phase. With his leadership, we are well-positioned to expand globally and deepen our impact across the biotech sector.”
Michael Bencak joins Cube Biotech with a proven track record of leading biotech organizations through growth, transformation, and innovation. With deep industry insight and a passion for advancing science, Bencak is poised to build on Cube Biotech’s legacy of excellence.
“I’m incredibly excited to join Cube Biotech and IBA Lifescience,” said Bencak. “These companies are uniquely positioned to shape the future of drug discovery. What inspired me to join is not only the science, but the passion, purpose, and ambition behind it. I truly believe we have the chance to make a meaningful difference.”
About Cube Biotech – Pioneering Protein Technologies to Enable Drug Discovery At Cube Biotech, we specialize in the purification, stabilization, and functional screening of proteins — tackling some of the most complex membrane protein targets in biomedical research. As enablers of drug discovery, we support scientists in unlocking the full therapeutic potential of proteins. Following our merger with IBA Life Sciences and with the strategic support of ARCHIMED, we are accelerating innovation, expanding our global reach, and streamlining services across the entire protein research value chain. Our latest advancement: a proprietary automation technology that enables scalable membrane protein production, providing researchers with the tools to drive structural biology, screening campaigns, and therapeutic development with exceptional efficiency and reproducibility.